Cyanovirin-N Binding to

Irene Maier, Georg Kontaxis, Christian Zimmermann, Christoph Steininger

Abstract read

In one paragraph

Article in Biochemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Artificial neural network guided optimization of tenofovir and Cyanovirin-N multipurpose preventive hydrogel formulation developed using the Box Behnken design model.Pharmaceutical science advances · 2025
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Irene MaierDepartment of Environmental Health Sciences, Fielding School of Public Health, University of California, Los Angeles, 650 Charles E. Young Dr. South, Los Angeles, California 90095, United States.ORCID 0000-0003-1471-6432

Georg KontaxisDepartment of Computational and Structural Biology, Max Perutz Laboratories, University of Vienna, Campus Vienna Biocenter 5, Vienna 1030, Austria.

Christian ZimmermannInstitute of Chemical, Environmental and Bioscience Engineering, TU Wien, Gumpendorfer Strasse 1a, Wien 1060, Austria.

Christoph SteiningerDepartment of Internal Medicine I, Medical University of Vienna, Waehringer Guertel 18-20, Vienna A-1090, Austria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cyanovirin-N (CV-N) binds high-mannose oligosaccharides on enveloped viruses with two carbohydrate-binding sites, one bearing high affinity and one low affinity to Manα(1-2)Man moieties. A tandem repeat of two CV-N molecules (CVN2) was tested for antiviral activity against human immunodeficiency virus type I (HIV-1) by using a domain-swapped dimer. CV-N was shown to bind

Indexed as

AcetylglucosamineBacterial ProteinsCarrier ProteinsBinding SitesHexosaminesHIV-1HumansModels, MolecularProtein BindingProtein MultimerizationAcetylglucosamineBacterial ProteinsCarrier Proteinscyanovirin NHexosaminesN-acetylmannosamine

Identifiers

PMID38770609

DOI10.1021/acs.biochem.4c00113

PMCPMC11112747

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.